Known targets — ChEMBL curated mechanism
CSF1RFLT1FLT3FLT4KDRKITPDGFRAPDGFRBRET
The experimentally established mechanism targets of Sunitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 16/20 | 0.92 |
| ▸ | PDGFRB known ✓ | P09619 | 7/20 | 0.92 |
| ▸ | CSF1R known ✓ | P07333 | 3/20 | 0.92 |
| ▸ | FLT3 known ✓ | P36888 | 3/20 | 0.92 |
| ▸ | RET known ✓ | P07949 | 2/20 | 0.92 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 0.92 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 0.92 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.92 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 0.92 |
| ▸ | PRKAA1 | Q13131 | 13/20 | 0.92 |
| ▸ | PRKAA2 | P54646 | 12/20 | 0.92 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.92 |
| ▸ | EGFR | P00533 | 3/20 | 0.92 |
| ▸ | PLK4 | O00444 | 2/20 | 0.92 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.92 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.92 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.92 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.92 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.92 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sunitinib SCHEMBL30197887 | 1.00 | KDR (0.92) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Sunitinib SCHEMBL28307868 | 1.00 | KDR (0.92) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Sunitinib SCHEMBL8081 | 0.96 | KDR (1.00) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Sunitinib SCHEMBL8082 | 0.96 | KDR (1.00) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Sunitinib SCHEMBL20805212 | 0.96 | KDR (1.00) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Sunitinib SCHEMBL25343935 | 0.96 | KDR (1.00) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Sunitinib SCHEMBL25343938 | 0.96 | KDR (1.00) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Sunitinib SCHEMBL30314241 | 0.96 | KDR (1.00) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Sunitinib SCHEMBL1779742 | 0.95 | KDR (0.95) | KDRPRKAA1PRKAA2PDGFRBFGFR1 | |
| Sunitinib SCHEMBL15265356 | 0.95 | KDR (0.95) | KDRPRKAA1PRKAA2PDGFRBFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4560 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122056884-A | Methods of treating pancreatic cancer | 坎莫森特里克斯公司 | 2026-05-19 | — | — | CN | claimed |
| US-12509465-B2 | Benzoimidazole derivatives as anticancer agents | CENTRE LEON BERARD (FR) | 2025-12-30 | — | — | US | claimed |
| US-20250213523-A1 | COMBINATION OF HDAC INHIBITORS AND STATINS FOR USE IN THE TREATMENT OF PANCREATIC CANCER | ISTITUTO NAZIONALE TUMORI IRCCS - FONDAZIONE G. PASCALE (IT) | 2025-07-03 | — | — | US | claimed |
| EP-4566675-A2 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2025-06-11 | — | — | EP | claimed |
| CN-119546293-A | Combination of HDAC inhibitors and statins for the treatment of pancreatic cancer | 国家癌症研究所IRCCS-G·帕斯卡莱基金会 | 2025-02-28 | — | — | CN | claimed |
| EP-4504165-A1 | COMBINATION OF HDAC INHIBITORS AND STATINS FOR USE IN THE TREATMENT OF PANCREATIC CANCER | Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale (IT) | 2025-02-12 | — | — | EP | claimed |
| US-12187743-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2025-01-07 | — | — | US | claimed |
| EP-4219492-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2024-11-27 | — | — | EP | claimed |
| CN-118267481-A | Construction and application of mRNA nano delivery system with environment adaptability and cooperative regulation | 浙江大学 | 2024-07-02 | — | — | CN | claimed |
| WO-2024085332-A1 | ANTIBODY-BOUND METAL-ORGANIC FRAMEWORK AND ANTICANCER COMPOSITION COMPRISING SAME | 울산과학기술원 | 2024-04-25 | — | — | WO | claimed |
| WO-2008055966-A1 | PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF TYROSINE KINASE INHIBITOR | ABBOTT GMBH & CO. KG (DE) | 2008-05-15 | — | — | WO | claimed |
| EP-1907444-A2 | POLYMERIC MICELLES FOR DRUG DELIVERY | Intezyne Technologies Incorporated (US) | 2008-04-09 | — | — | EP | claimed |
| US-20080003219-A1 | DELIVERY OF AN OCULAR AGENT | MINU, L.L.C. (US) | 2008-01-03 | — | — | US | claimed |
| US-20070281934-A1 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2007-12-06 | — | — | US | claimed |
| WO-2007109178-A2 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2007-09-27 | — | — | WO | claimed |
| WO-2007038453-A2 | USE OF AN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AGENT TO AMELIORATE INFLAMMATION | ADVANCED OCULAR SYSTEMS LIMITED (AU) | 2007-04-05 | — | — | WO | claimed |
| US-20070072933-A1 | Delivery of an ocular agent | MINU, LLC | 2007-03-29 | — | — | US | claimed |
| US-20070071756-A1 | Delivery of an agent to ameliorate inflammation | MINU, LLC | 2007-03-29 | — | — | US | claimed |
| US-20060240092-A1 | drug loaded micelle of a triblock polymer tert-butylphenylsilylpropene-polyethylene glycol-b-poly(tert-butylaspartic acid-b-polyphenylalanine-copoly( tert-buyltyrosine) has a drug-loaded inner core, a crosslinked outer core, and a hydrophilic shell | INTEZYNE TECHNOLOGIES, INC. | 2006-10-26 | — | — | US | claimed |
| WO-2006107903-A2 | POLYMERIC MICELLES FOR DRUG DELIVERY | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2006-10-12 | — | — | WO | claimed |